Positron emission tomography imaging of cell proliferation in oncology.
Affiliation
Molecular Therapy Group and PET Oncology Group, Hammersmith Hospital, London, UK.Issue Date
2004-05
Metadata
Show full item recordAbstract
Tumour-cell proliferation is a hallmark of the malignant phenotype. Positron emission tomography (PET) offers a unique method of imaging biological and biochemical changes in vivo. Radiolabelled thymidine and thymidine analogues are currently in development as PET tracers. By studying the uptake and kinetics of such compounds using PET, a measure of DNA synthesis and hence cell proliferation can be obtained. Molecular imaging of cellular proliferation with PET is now possible, and has the potential to play an important role in the evaluation of efficacy of new anti-cancer agents.Citation
Positron emission tomography imaging of cell proliferation in oncology. 2004, 16 (3):176-85 Clin OncolJournal
Clinical OncologyPubMed ID
15191004Type
ArticleLanguage
enISSN
0936-6555Collections
Related articles
- Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive evaluation.
- Authors: Barwick T, Bencherif B, Mountz JM, Avril N
- Issue date: 2009 Dec
- Pharmacodynamics of radiolabelled anticancer drugs for positron emission tomography.
- Authors: Hutchinson OC, Collingridge DR, Barthel H, Price PM, Aboagye EO
- Issue date: 2003
- PET imaging of cellular proliferation.
- Authors: Mankoff DA, Shields AF, Krohn KA
- Issue date: 2005 Jan
- Measuring tumor pharmacodynamic response using PET proliferation probes: the case for 2-[(11)C]-thymidine.
- Authors: Wells P, West C, Jones T, Harris A, Price P
- Issue date: 2004 Dec 17
- PET imaging of tumor growth: not as easy as it looks.
- Authors: Shields AF
- Issue date: 2012 Mar 1